



# Freiburg Medical Laboratory Middle East (L.L.C)

P.O. Box: 3068, Dubai - UAE, Tel: 04 396 2227, Fax: 04 396 2228

E-mail: info@fml-dubai.com, Website: www.fml-dubai.com

## Physician:

Dr. M. Jaksch  
Freiburg Medical Lab

## Laboratory Report Online Version

Report Date: 08.05.2018

### Patient Name: Sample report

Gender: Male  
Date of Birth: 01.01.1980  
Nationality:  
Your ID:

Test Request Code: 1695  
Sample ID:  
Patient IDNo: 380411

Sampling Date / Time: 08.05.2018 / 12:30  
Receipt Date / Time: 08.05.2018 / 12:43

### Remarks:

### Insurance:

Analysis	Result	Flag	Units	Reference Range
----------	--------	------	-------	-----------------

#### Proteins/Metabolites (EDTA-Plasma)

<b>Homocysteine (PHO)</b>	<b>10.5</b>		umol/l	<12.0
---------------------------	-------------	--	--------	-------

#### Please note:

We are using the cut-off value of 12 umol/l, which is used in European laboratories. In most of the U.S. laboratories, 15 umol/l is used as the cut-off value for normal levels of Homocysteine in adults.

A significantly increased level of homocysteine is considered an arteriosclerotic risk factor.

Various studies have shown that the risk of mortality will not be increased by results below 10; results from 10 to 15 increase the risk factor up to 1.9 times;

results from 15 to 20 up to 2.8 times; results >20 up to 4.5 times.

A combined folic acid, vitamin B6 and vitamin B12 supplementation followed by homocysteine level monitoring is recommended.

Please note, that the reference range is valid only for serum/plasma which was separated within one hour after blood collection.

#### Proteins/Metabolites (Serum)

<b>CRP high sensitive (TURB)*</b>	<b>0.07</b>		mg/dl	< 0.10
-----------------------------------	-------------	--	-------	--------

#### Cardiovascular risk:

low < 0.1

medium 0.1 - 0.3

high > 0.3

<b>LDL, Oxidized (EIA)*</b>	<b>137</b>		ng/ml	20 - 170
-----------------------------	------------	--	-------	----------

<b>Lipoprotein (a) (TURB)</b>	<b>55.0</b>		nmol/l	< 75.0
-------------------------------	-------------	--	--------	--------

Elevated lipoprotein (a) increases the risk for CHD in combination with

#### Note:

Our reference values are adjusted to age and gender.

Daily internal Quality Control within the required range (according to ISO 15189).

External Quality Control available on request.

^ non-accredited parameter

\* This parameter is affected by Biotin intake of >5 mg (RDI = 0.03mg)

\* This investigation has been performed in a collaborating accredited laboratory (Germany).

Techn. Validation by  
Med. Technologist  
(Supervisor of  
the Department)

Dr. Nehmat EIBanna  
Specialist  
Clinical Pathology (U/S)  
(DHA-P-0084548)

PD Dr. med. habil. M. Jaksch  
Associate Professor  
Medical Director  
(DHA-LS-240710)

This report has been printed through Imed-Online-Reporting-System and therefore does not carry a signature.



# Freiburg Medical Laboratory Middle East (L.L.C)

P.O. Box: 3068, Dubai - UAE, Tel: 04 396 2227, Fax: 04 396 2228

E-mail: info@fml-dubai.com, Website: www.fml-dubai.com

## Physician:

Dr. M. Jaksch  
Freiburg Medical Lab

## Laboratory Report Online Version

Report Date: 08.05.2018

### Patient Name: Sample report

Gender: Male  
Date of Birth: 01.01.1980  
Nationality:  
Your ID:

Test Request Code: 1695  
Sample ID:  
Patient IDNo: 380411

Sampling Date / Time: 08.05.2018 / 12:30  
Receipt Date / Time: 08.05.2018 / 12:43

### Remarks:

### Insurance:

### Analysis

### Result

### Flag

### Units

### Reference Range

other CHD risk factors. A moderately strong association of Lp (a) with CHD has been established independently of the classical vascular risk factors.

The risk of angina pectoris is increased with high concentration of Lp (a) and it is more significant if accompanied by high LDL-C concentration.

Treatment with Niacin reduces Lp (a) levels by 30-40% and yields other potential beneficial effects by reducing LDL cholesterol, total cholesterol, triglycerides, remnant cholesterol and by raising HDL cholesterol.

Ref: Borge G. Nordestgaard, M. John Chapman, Kausik Ray et al. for the European Atherosclerosis Society Consensus Panel: Lipoprotein (a) as a cardiovascular risk factor: current status.

Source: European Heart Journal: 2010; 31:2844-2853

**BNP-NT-Propeptide (LIA)\*** **88** ng/l < 125

Normal values exclude heart insufficiency to > 96%.

### Proteins/Metabolites (Serum, fasting)

#### Lipoprint

Parameter	Result	Flag	Units	Reference Range
<b>Cholesterol (PHO)*</b>	<b>168</b>		mg/dl	100 - 200
<b>VLDL- Lipoprotein (GEL)*</b>	<b>29</b>	<b>high</b>	mg/dl	up to 22
<b>Inter Lip-Cholesterol(C)(GEL)*</b>	<b>13</b>		mg/dl	up to 23
<b>Inter Lip-Cholesterol(B)(GEL)*</b>	<b>10</b>		mg/dl	up to 15
<b>Inter Lip-Cholesterol(A)(GEL)*</b>	<b>13</b>		mg/dl	up to 25
<b>Large LDL-Cholesterol(1)(GEL)*</b>	<b>41</b>		mg/dl	up to 57
<b>Large LDL-Cholesterol(2)(GEL)*</b>	<b>22</b>		mg/dl	up tp 30
<b>Small LDL-Cholesterol(3)(GEL)*</b>	<b>3</b>		mg/dl	up to 6

#### Note:

Our reference values are adjusted to age and gender.  
Daily internal Quality Control within the required range  
(according to ISO 15189).

External Quality Control available on request.

^ non-accredited parameter

\*This parameter is affected by Biotin intake of >5 mg  
(RDI = 0.03mg)

\* This investigation has been performed in a collaborating  
accredited laboratory (Germany).

Techn. Validation by  
Med. Technologist  
(Supervisor of  
the Department)

Dr. Nehmat EIBanna  
Specialist  
Clinical Pathology (U/S)  
(DHA-P-0084548)

PD Dr. med. habil. M. Jaksch  
Associate Professor  
Medical Director  
(DHA-LS-240710)

This report has been printed through Imed-Online-Reporting-System and therefore does not carry a signature.



# Freiburg Medical Laboratory Middle East (L.L.C)

P.O. Box: 3068, Dubai - UAE, Tel: 04 396 2227, Fax: 04 396 2228

E-mail: info@fml-dubai.com, Website: www.fml-dubai.com

## Physician:

Dr. M. Jaksch  
Freiburg Medical Lab

## Laboratory Report Online Version

Report Date: 08.05.2018

### Patient Name: Sample report

Gender: Male  
Date of Birth: 01.01.1980  
Nationality:  
Your ID:

Test Request Code: 1695  
Sample ID:  
Patient IDNo: 380411

Sampling Date / Time: 08.05.2018 / 12:30  
Receipt Date / Time: 08.05.2018 / 12:43

### Remarks:

### Insurance:

Analysis	Result	Flag	Units	Reference Range
<b>Proteins/Metabolites (Serum, fasting), Continuation</b>				
Small LDL-Cholesterol(4)(GEL)*	0		mg/dl	0
Small LDL-Cholesterol(5)(GEL)*	0		mg/dl	0
Small LDL-Cholesterol(6)(GEL)*	0		mg/dl	0
Small LDL-Cholesterol(7)(GEL)*	0		mg/dl	0
HDL - Lipoprotein (GEL)*	38	low	mg/dl	> 40

Phenotype A, no increased atherogenic risk. Predominantly large and less atherogenic particles are detected in LDL-subfractions.

Further recommended complementary tests in serum: Apolipoprotein A1, B.

#### Note:

Our reference values are adjusted to age and gender.  
Daily internal Quality Control within the required range  
(according to ISO 15189).

External Quality Control available on request.

^ non-accredited parameter

\* This parameter is affected by Biotin intake of >5 mg  
(RDI = 0.03mg)

\* This investigation has been performed in a collaborating  
accredited laboratory (Germany).

Techn. Validation by  
Med. Technologist  
(Supervisor of  
the Department)

Dr. Nehmat ElBanna  
Specialist  
Clinical Pathology (U/S)  
(DHA-P-0084548)

PD Dr. med. habil. M. Jaksch  
Associate Professor  
Medical Director  
(DHA-LS-240710)

This report has been printed through Imed-Online-Reporting-System and therefore does not carry a signature.